Clinical

Dataset Information

0

Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab


ABSTRACT: Interventions: 1) Bevacizumab 10mg/kg is administered by 10-30min. intravenous infusion, followed by irinotecan 150mg/m2 by 90 min infusion (2)Patients should be received this chemotherapy biweekly until disease progression Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620667 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2622484 | ecrin-mdr-crc
| PRJNA93351 | ENA
| S-EPMC3725595 | biostudies-literature
| 2623833 | ecrin-mdr-crc
| 2623074 | ecrin-mdr-crc
| 2643378 | ecrin-mdr-crc
| 2624679 | ecrin-mdr-crc
| 2640977 | ecrin-mdr-crc
2007-03-01 | GSE7146 | GEO
2021-07-15 | PXD026470 | JPOST Repository